Target intelligence / Profile preview

Limbic system-associated membrane protein (LSAMP)

Target
LSAMP
Molecular classification
Cell adhesion molecule, Immunoglobulin superfamily (IgCAM), IgLON family, Transmembrane glycoprotein
01

Overview

Limbic system-associated membrane protein (LSAMP) is a cell adhesion molecule that belongs to the immunoglobulin superfamily, specifically the IgLON family of proteins. It is critical in the central nervous system, especially within the limbic system, for regulating neural development, axon guidance, and synaptic plasticity. LSAMP acts as a homophilic adhesion molecule, supporting the formation and maintenance of neural circuits involved in learning, memory, and emotional behavior. It is also proposed to act as a tumor suppressor, with loss or dysregulation associated with increased cancer risk in several tissues. Dysregulation of LSAMP has been linked to neuropsychiatric conditions, neurodegenerative disease, and a variety of tumor types. No drugs are currently known to directly target LSAMP.

Other names
Limbic system-associated membrane proteinLSAMPIGLON3LAMPIgLON family member 3
02

Mechanism of action

Not applicable; no drugs are known to directly target LSAMP. Its tumor suppressor function is mediated by modulation of cell adhesion and inhibition of receptor tyrosine kinase signaling in cancer contexts.

03

Biological functions

Cell adhesionNeuronal developmentSynaptic plasticityAxon guidanceNeural circuit remodelingTumor suppressionEmotional and behavioral regulation
04

Disease associations

Neuropsychiatric disorders (e.g., schizophrenia, mood disorders)Intellectual disabilityNeurodegenerative diseases (e.g., Alzheimer’s disease)Cancer (e.g., clear cell renal cell carcinoma, prostatic adenocarcinoma, lung adenocarcinoma, osteosarcoma, neuroblastoma, AML, ovarian cancer)
05

Safety considerations

None specifically reported for targeting LSAMP; as it is essential in neural development and synaptic function, hypothetically, unwanted effects could include neurodevelopmental or cognitive disturbances.
06

Biomarkers

LSAMP gene deletion, methylation, or downregulation as a biomarker for certain cancers (e.g., clear cell renal cell carcinoma, lung, prostate, osteosarcoma, neuroblastoma)Potential biomarker for neuropsychiatric and neurodevelopmental disorders

Beyond the preview

Go deeper on Limbic system-associated membrane protein (LSAMP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Limbic system-associated membrane protein (LSAMP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call